Dan is the Human Experimental Biology Lead in the Computational Neuromedicine and Experimental Human Biology line within the Neuroscience Research Unit in WRD where he manages the implementation and execution of Pfizer’s collaborative Human Neurophenotyping Centers, ensuring that asset teams have access to and an understanding of the value that these centers bring to the clinical development paradigm. He is active in the mobile sensing space, investigating technologies, their applicability to neuropsychiatric drug development, rational pathways for their validation and integration, with a strategy of data management, analysis, and interpretation. Dan is also the primary point of contact for our Clinical Translational Fellowship program participants.
Following graduation from the College of Columbia University with an undergraduate degree in neuroscience and behavior, Dan worked in emergency medical services and disaster response including the World Trade Center Collapse, concurrently he designed and built information systems to support rescue and response efforts. He formalized this informatics experience while working toward an M.A. in clinical informatics and cognition in medicine at the Graduate School of Arts and Sciences at Columbia University. Dan went on to earn his M.D. from the University of Colorado School of Medicine where he served as an informatics advisor to the state medical society. His internship in pediatrics, and residency training in psychiatry at Tufts Medical Center, where he was recognized with multiple excellence in teaching awards from Tufts University School of Medicine and was the recipient of the American College of Psychiatrist’s Laughlin Fellowship, lead to board certification in psychiatry and subsequent appointment to the Tufts Medical Center attending staff as well as a faculty appointment at the school of medicine. In this role he served as the hospital’s head physician for informatics and the Director of Psychiatry Informatics, leading the planning, implementation, and execution of a number of projects while also serving as the first participant in the inaugural year of the Tufts/Pfizer Clinical Translational Fellowship.